Evidence Hub

Tadalafil treatment for fetus with early onset growth restriction (TADAFER) A multicenter phase II trial: 374

Shintaro Maki, Hiroaki Tanaka, S. Magawa, M. Tsuji, F. Furuhashi, M. Nii, K. Toriyabe, M. Kaneda et al.

American Journal of Obstetrics and Gynecology, 2019

1 citation

Abstract

373 Effect of maternal body mass index on inpatient postpartum opioid use Shelly Soni, Matthew J. Blitz, Lakha Prasannan, Meir Greenberg, Michael Qiu, Shreya Sanghani, Burton Rochelson, Harvey Marchbein Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, Feinstein Institute for Medical Research, Manhasset, NY OBJECTIVE: To evaluate the effect of maternal body mass index (BMI) on the administration of postpartum analgesic medications, especially the use of opioids. For many women, postpartum period represents the first exposure to opioids. Therefore, it is important to better elucidate the factors influencing the use of these medications. STUDY DESIGN: Retrospective cohort study of singleton deliveries at 37 weeks of gestation at a tertiary university hospital from 2013 -2016. Patients were excluded for the following: illicit drug use, positive urine toxicology, NSAID or opioid allergies, current smokers, and incomplete records. All standard analgesic medications administered during postpartum hospitalization were reviewed, including the dose and route of administration. Chi-square, Fisher’s exact test and analysis of variance (ANOVA) were used where appropriate. Multivariate linear regression models were used to identify factors associated with the use of oxycodone in the postpartum period. RESULTS: A total of 16,085 pregnancies were included: 5,565 cesarean delivery (CD) and 10,520 vaginal delivery (VD). Women in each mode of delivery (MOD)…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free